Akebia, Mitsubishi Tanabe Pharma deal

Akebia granted Mitsubishi exclusive rights to develop and commercialize vadadustat in Japan, Taiwan, Indonesia, East Timor, South Korea, Mongolia, the Philippines, Vietnam, Laos, Cambodia, Thailand, Malaysia, Singapore, Brunei, Myanmar, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Palau, Tonga and India. Akebia will continue to lead global clinical trials and plans to begin Phase III testing of vadadustat by year end to treat anemia in non-dialysis chronic kidney disease (CKD) patients and by mid-2016 to treat anemia in dialysis-dependent CKD patients. Mitsubishi will lead commercialization. ...